Karolinska Dev

Karolinska Development AB (SSE: KDEV) is an investment company focused on identifying medical innovation and supporting the creation and growth of companies

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company PharmNovo reports positive results from a clinical phase 1 study of drug candidate PN6047 https://t.co/UMMJuwffWb

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company PharmNovo reports promising preclinical results on abuse potential and withdrawal symptom relief for its candidate drug PN6047 https://t.co/gSaJlP6BpA

[Karolinska Dev @Karolinska_Dev]

Karolinska Development's portfolio company OssDsign raises SEK 150 million and makes strategic move to become a pure play orthobiologics company https://t.co/EgIybjRqaR

[Karolinska Dev @Karolinska_Dev]

Karolinska Development's portfolio company OssDsign has received FDA clearance for a new major indication https://t.co/Bhzmy4pEhv

[Karolinska Dev @Karolinska_Dev]

Interim Report - January-June 2023 https://t.co/zrep5L1bfN

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone in a preclinical model of Parkinson’s disease https://t.co/4sdNVtFDdn

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Umecrine Cognition presents data on golexanolone’s mode-of-action and ability to reduce neuroinflammation https://t.co/as9ydtyCkS

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s Annual General Meeting 2023 https://t.co/etPCD9o0cn

[Karolinska Dev @Karolinska_Dev]

Karolinska Development's portfolio company Modus Therapeutics sees potential for its drug candidate sevuparin in the treatment of anemia https://t.co/oeE1RaRCSu

[Karolinska Dev @Karolinska_Dev]

Interim Report - January-March 2023 https://t.co/RL2U1jf8B6

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Umecrine Cognition includes first patient in Phase 2 study of golexanolon in primary biliary cholangitis https://t.co/Yq2WL2rtPb

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company AnaCardio recruits first patient to a clinical trial of its drug candidate AC01 https://t.co/Wp8DjF0P2N

[Karolinska Dev @Karolinska_Dev]

Notice of Annual General Meeting in Karolinska Development AB (publ) https://t.co/IugjTjihBd

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Umecrine Cognition secures additional funding for further development of golexanolone https://t.co/m5aJoW8mTc

[Karolinska Dev @Karolinska_Dev]

Karolinska Development Annual Report 2022 published https://t.co/BfmkQRZg2F

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company AnaCardio’s founder publishes article that supports development of heart failure drug candidate AC01 https://t.co/ZOtHqMTVzU

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Biosergen presents positive results from phase 1 study of drug candidate to treat systemic fungal infection https://t.co/BvXyBadi3I

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company SVF Vaccines initiates clinical phase 1 study of its universal Covid-19 vaccine https://t.co/ehZjMBxCG3

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Aprea Therapeutics secures funding of USD 5.5 million https://t.co/oNctcSVoZ1

[Karolinska Dev @Karolinska_Dev]

Karolinska Development’s portfolio company Modus Therapeutics presents positive results from a clinical trial of sevuparin https://t.co/4So1kaxVOV